Clinical Trial Update: Single Ascending Dose Study of Oral CPSI-2364 (Semapimod) [Phase 1]

View source ↗

Summary

This update reports completion of a Phase 1 single ascending dose study of CPSI-2364 (semmapimod) in Crohn's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• CPSI-2364 (Semapimod) (Semapimod)

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Crohn's Disease | Phase 1 | Status: COMPLETED